¹*PKHD1L1***, A Gene Involved in the Stereociliary Coat, Causes Autosomal** ²**Recessive Nonsyndromic Hearing Loss**

- 4 Shelby E. Redfield^{1,+}, Pedro De-la-Torre^{2,3,+}, Mina Zamani^{4,5}, Hina Khan⁶, Tyler Morris²,
- 5 Gholamreza Shariati^{5,7,}, Majid Karimi⁸, Margaret A. Kenna^{1, 2}, Go Hun Seo⁹, Sadaf Naz⁶, Hamid
- 6 Galehdari⁴, Artur A. Indzhykulian^{2,3,*,} ^, A. Eliot Shearer^{1, 3,*},^, Barbara Vona^{10,11,*,}^
- 7 1. Department of Otolaryngology and Communication Enhancement, Boston Children's 8 Hospital, 300 Longwood Avenue, BCH-3129, Boston, MA 02115, USA
- 9 2. Mass Eye and Ear, Eaton Peabody Laboratories, Boston, Massachusetts, USA
- 10 3. Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, 25 Shattuck
- 11 Street, Boston, MA 02115, USA
- 12 4. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
- 13 5. Narges Medical Genetics and Prenatal Diagnosis Laboratory, Kianpars, Ahvaz, Iran
- 14 6. School of Biological Sciences, University of the Punjab, Quaid-e-Azam Campus, Lahore 15 54590, Pakistan
- 16 7. Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of
- 17 Medical Sciences, Ahvaz, Iran
- 18 8. Khuzestan Cochlear Implantation Center (Tabassom), Ahvaz, Iran
- 19 9. 3billion, Inc., Seoul, South Korea
- 20 10. Institute of Human Genetics, University Medical Center Göttingen, 37073 Göttingen, 21 Germany
- 22 11. Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen,
- 23 37075 Göttingen, Germany
- 24 ** Corresponding authors*: Artur_Indzhykulian@hms.harvard.edu, 25 Eliot.Shearer@childrens.harvard.edu, barbara.vona@med.uni-goettingen.de
- 26 *+ Contributed equally to this work*
- 27 *^ Contributed equally to this work*
- 28

3

¹**ORCID**

¹**Abstract**

2 Identification of genes associated with nonsyndromic hearing loss is a crucial endeavor, given 3 the substantial number of individuals who remain without a diagnosis after even the most 4 advanced genetic testing. *PKHD1L1* was established as necessary for the formation of the 5 cochlear hair-cell stereociliary coat and causes hearing loss in mice and zebrafish when 6 mutated. We sought to determine if biallelic variants in *PKHD1L1* also cause hearing loss in 7 humans.

8 Exome sequencing was performed on DNA of three families segregating autosomal recessive 9 moderate to severe nonsyndromic sensorineural hearing loss. Compound heterozygous 10 missense p.[(Gly129Ser)];p.[(Gly1314Val)], homozygous missense p.(His2479Gln) and 11 nonsense p.(Arg3381Ter) variants were identified in *PKHD1L1* that were predicted to be 12 damaging using *in silico* pathogenicity prediction methods. *In vitro* functional analysis of two 13 missense variants was performed using purified recombinant PKHD1L1 protein fragments. We 14 then evaluated protein thermodynamic stability with and without the missense variants found in 15 one of the families. *In vitro* functional assessment indicated that both engineered PKHD1L1 16 mutant p.(Gly129Ser) and p.(Gly1314Val) constructs significantly reduced the folding and 17 structural stabilities of the expressed protein fragments, providing further evidence to support 18 pathogenicity of these variants. *In silico* molecular modelling using AlphaFold2 and protein 19 sequence alignment analysis were carried out to further explore potential variant effects on 20 protein folding and stability and exposed key structural features that might suggest PKHD1L1 21 protein destabilization.

22 Multiple lines of evidence collectively associate *PKHD1L1* with nonsyndromic mild-moderate to 23 severe sensorineural hearing loss. *PKHD1L1* testing in individuals with mild-moderate hearing 24 loss may identify further affected families.

25

26 **Keywords:** Polycystic Kidney and Hepatic Disease 1-Like 1 (*PKHD1L1*), stereocilia, deafness

²⁷**Introduction**

28 Hearing loss-associated genes are implicated in the function of all parts of the delicate 29 molecular machinery that permits human hearing. The inner hair cells (IHCs) and outer hair 30 cells (OHCs) of the organ of Corti contain an apical bundle of ~100 actin-filled protrusions called 31 stereocilia. Upon sound stimulation, stereocilia bundles are deflected by pressure-induced 32 waves within the fluid-filled organ of Corti. Housing the mechanotransduction apparatus at the 33 tips of stereocilia, these bundles mediate the transformation of the mechanical stimulus into an 34 electrical signal the brain interprets as sound. While IHCs convert sound waves into nerve 35 signals, OHCs allow for non-linear amplification of the sound stimuli by changing their length in 36 response to bundle deflection, a process known as electromotility (Brownell 1990). Although 37 IHCs and OHCs have two separate and distinct functions, both sensory cell types require a 38 properly organized, functional stereocilia bundle. Stereocilia have a transiently expressed 39 surface coat, but little is understood about the function or molecular architecture of this surface 40 specialization. To date, there are over 30 genes reported to be critical for stereocilia bundle 41 morphology that are associated with sensorineural hearing loss (SNHL) in humans (Michalski 42 and Petit 2015; Petit and Richardson 2009).

43 One such stereocilia protein, polycystic kidney and hepatic disease 1-like 1 (*Pkhd1l1*) is critical 44 to hearing in mice (Wu et al. 2019). The *PKHD1L1* gene in humans encodes a 4,243 amino acid 45 protein, which is predicted to be composed by a large extracellular domain, a 20 amino acid 46 transmembrane domain, and a very short cytoplasmic domain of 9 residues. In mice, PKHD1L1 47 is highly enriched in both IHCs and OHCs, particularly at the tips of OHC stereocilia bundles 48 (Wu et al. 2019). It is hypothesized that this protein makes up a major component of the 49 transient stereociliary coat. Mice lacking *Pkdh1l1* displayed elevated Auditory Brainstem 50 Response (ABR) and Distortion Product Otoacoustic Emissions (DPOAE) thresholds in 51 response to pure tone stimuli in a progressive fashion (Wu et al. 2019). More recent data from 52 zebrafish (*Danio rerio*) with a double knockout of *pkhd1l1a* and *pkhd1l1b* (orthologs of human 53 *PKHD1L1*) show significant deficits in auditory startle response at the larval stage, consistent 54 with an early-onset auditory phenotype in zebrafish (Makrogkikas et al. 2023). Based on these 55 findings in animal models, we sought to determine whether variants in *PKHD1L1* cause hearing 56 loss in humans.

57 In this study, we propose *PKHD1L1* as a novel cause of autosomal recessive nonsyndromic 58 hearing loss in humans. We describe three unrelated families with biallelic variants in *PKHD1L1* 59 identified via exome sequencing. All three probands present bilateral congenital SNHL which is

60 moderate to severe. In addition, *in vitro* functional evaluation of two of the missense variants in

 61 protein fragments show decreased stabilities, suggesting that they may negatively impact their

62 structures and molecular assembly *in vitro*.

⁶³**Methods**

64 **Recruitment and Clinical Assessment**

65 This study was approved by the institutional review boards of Boston Children's Hospital (IRB P-66 00031494), University Medical Center Göttingen (No. 3/2/16), and the School of Biological 67 Sciences, University of Punjab, Lahore, Pakistan (IRB No. 00005281). Written informed consent 68 was obtained from participating members of the three families or parents for their minor 69 children.

70 The proband in family 1 derived from non-consanguineous parents ascertained as part of a 71 large clinically diverse cohort of patients with SNHL in the United States. The proband in family 72 2 derived from consanguineous parents and was ascertained as part of a large ethnically 73 diverse Middle Eastern population rare disease study. The proband in family 3 was born to 74 consanguineous parents and identified from a special education school. The parents did not 75 participate in the study.

76 Demographic, otolaryngologic, audiological, and relevant medical data were ascertained from 77 the medical records of probands. Affected individuals underwent a complete otologic evaluation. 78 Routine pure-tone audiometry was performed according to current standards and measured 79 hearing thresholds at 0.25, 0.5, 1, 2, 4, 6 and 8 kHz. Pure tone audiometry for proband 3 was 80 performed in ambient noise conditions due to lack of soundproof testing environment. The 81 probands in families 1 and 2 underwent tympanometry and speech audiometry testing. Proband 82 2 additionally underwent otoacoustic emissions testing.

83 **Exome Sequencing**

84 Genomic DNA (gDNA) from individuals in families 1 (I:1, I:2 and II:1), 2 (III:1, III:2, IV:1 and IV:2) 85 and 3 (II:1) was isolated from either buccal mucosa or whole blood using standard procedures.

86 *Family 1:* Exome sequencing was performed in a Clinical Laboratory Improvements 87 Amendments (CLIA)-certified environment (GeneDx, Gaithersburg, MD, USA). Analysis was 88 performed using the DRAGEN pipeline (Illumina, San Diego, CA, USA). Copy number variants 89 were annotated using genome analysis toolkit (GATK) and a normalized segmented depth of 90 coverage model. Variants were prioritized according to allele frequency, *in silico* predictors,

91 variant segregation, prior observations, and gene-disease association, as previously described 92 (Rockowitz et al. 2020).

93 *Family 2*: Exome sequencing for the proband was performed using the SureSelect Target 94 Enrichment v7 (Agilent Technologies, Santa Clara, CA) kit and sequenced with a NovaSeq 95 6000 (Illumina, San Diego, CA, USA) sequencer following manufacturer's protocols. 96 Bioinformatics analysis of the proband in family 2 was performed as previously described (Vona 97 et al. 2021).

98 *Family 3:* Exome sequencing for the proband was carried out at 3billion, Inc., Seoul, South 99 Korea (https://3billion.io/index). Briefly, coding exon regions of human genes (~22,000) were 100 captured by xGen Exome Research Panel v2 (Integrated DNA Technologies, Coralville, IA, 101 USA). The captured regions of the genome were sequenced with NovaSeq 6000 (Illumina, San 102 Diego, CA, USA). The raw genome sequencing data analysis, including alignment to the 103 GRCh37/hg19 human reference genome, variant calling and annotation, was conducted with 104 open-source bioinformatics tools including Franklin (https://franklin.genoox.com/clinical-105 db/home) and 3billion in-house software.

106 **Variant Assessment and Validation**

107 Variants were prioritized based on population and *in silico* pathogenicity prediction software. 108 Variant minor allele frequencies were derived from gnomAD (v2.1.1 and v3.1.2) (Chen et al. 109 2022; Karczewski et al. 2020). Various pathogenicity prediction tools were used including SIFT 110 (Ng and Henikoff 2001), PolyPhen-2 (Adzhubei et al. 2010), FATHMM (Shihab et al. 2014), 111 MutationTaster (Schwarz et al. 2014), REVEL (Ioannidis et al. 2016) and CADD (Rentzsch et al. 112 2019). Visualization of amino acid substitution tolerance was supported by the MetaDome web 113 server (Wiel et al. 2019).

114 Variants were annotated using the *PHKD1L1* NM_177531.6 accession (ENST00000378402.9).

115 The GTEx Portal (GTEx consortium 2013) was referenced for assessing the location of variants 116 across the annotated PHKD1L1 isoform (Supplementary Fig. S1).

117 *PKHD1L1* variant segregation in families 1 and 2 was confirmed using Sanger sequencing.

118 Confirmation via Sanger sequencing was not performed for the proband of family 3.

119 **Sequence analyses and structural modeling of PKHD1L1 protein**

120 We compared the PKHD1L1 isoform sequence among 10 different species (see Supplementary 121 Table S1 for more details about the selected species). The sequences were obtained from the

122 National Center for Biotechnology Information (NCBI) protein database (Supplementary Table 123 S1). First, each individual protein sequence was used to predict their signal peptides and 124 domains using the Simple Modular Architecture Research Tool (SMART) (Letunic et al. 2021). 125 Signal peptides were further predicted using the SignalP-5.0 (Almagro Armenteros et al. 2019) 126 and the Prediction of Signal Peptides (PrediSi) online servers (Hiller et al. 2004). AlphaFold2 127 modelling was used to predict the potential signal peptide cleavage site and accurately inform 128 the start and end of each predicted domain before carrying out the protein sequence alignment 129 (Mirdita et al. 2022). Since the PKHD1L1 IPT domains do not have a clear conservation pattern 130 at their IPT protein start and end sequence and connecting linker domains, AlphaFold2 131 modeling results were then combined with protein sequence alignment to better predict the 132 signal peptide, IPT domain start and end residue positions, and the location of missense 133 mutations.

134 The ClustalW algorithm (Larkin et al. 2007) on Geneious (Kearse et al. 2012) was used for the 135 sequence identity analysis using the default parameters. Alignment files from Geneious were 136 imported and color-coded in JalView with 35% conservation threshold, as previously described 137 (Kearse et al. 2012). AlphaFold2 simulations of PKHD1L1 fragments were carried out using the 138 Colabfold v1.5.2-patch server using default parameters (Mirdita et al. 2022).

139 **Cloning, expression, and purification of engineered bacterially expressed PKHD1L1** 140 **protein fragments and mutant constructs**

141 Wild-type (WT) *Mus musculus* (*Mm*) PKHD1L1 IPT1-3 and IPT5-6 were subcloned into the *Nde*I 142 and *Xho*I sites of the pET21a+ vector. Site-directed mutagenesis was applied to engineer the 143 *Mm* PKHD1L1 IPT1-3 p. (Gly129Ser) and PKHD1L1 IPT5-6 p. (Gly1314Val) constructs using the 144 QuickChange lightning kit (Agilent Technologies). All constructs were used for protein 145 expression in Rosetta (DE3) competent cells (Novagen) and cultured in TB as reported 146 previously (De-la-Torre et al. 2018). Expressed proteins were refolded at 4 °C using conditions 147 outlined below. WT *Mm* PKHD1L1 IPT1-3 and IPT1-3 p.(Gly129Ser) were refolded by fast or 148 drop-wise dilution as previously reported for other protein families (De-la-Torre et al. 2018): 149 20 mL of pure denatured protein (0.5-1 mg/mL) was dropped into 480 mL of refolding buffer 150 containing 20 mM TrisHCl [pH 8.0], 150 mM KCl, 50 mM NaCl, 2 mM CaCl₂, 400 mM L-arginine, 151 and 2 mM D(+) glucose. *Mm* WT PKHD1L1 IPT5-6 and IPT5-6 p.(Gly1314Val) were refolded by 152 dialysis of 40 mL of eluted denatured protein at 0.5 mg/mL into 1000 mL of refolding buffer (20 153 mM TrisHCl [pH 7.5], 150 mM KCl, 50 mM NaCl, 5 mM CaCl₂, 400 mM L-arginine, 1 mM of 154 glutathione oxidized). Proteins were concentrated using 10,000 Da Amicon Ultra-15 centrifugal

155 filters and purified using size exclusion chromatography with an Akta Purifier System with the 156 S200 16/600 pg and S200 13/300 increase GL columns (GE Healthcare) in a buffer containing 157 20 mM Tris-HCl pH 7.5, 150 mM KCl, 50 mM NaCl, and 5 mM CaCl₂ to preserve the most 158 abundant endolymphatic cations. Purity of the recombinant and mammalian proteins was 159 analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

160 **Nanoscale Differential Scanning Fluorimetry**

161 WT *Mm* PKHD1L1 IPT1-3 and IPT5-6 protein fragments and their respective missense IPT1-3 162 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) proteins were used for functional evaluation *in vitro*. 163 Thermodynamic evaluation and folding stabilities of these constructs in solution were carried out 164 using nano differential scanning fluorimetry (NanoDSF). Pure proteins were concentrated to 0.5- 165 1 mg/mL for NanoDSF using a Prometheus NT.48 (Nanotemper) and scanned between 20-95 166 °C with a pre-stabilization phase of 1 min and a temperature slope of 2 °C/min (37 min in total). 167 Data were processed using a PR.ThermControl v2.1.2 software and plotted using GraphPad 168 Prism. At least two biological replicates were used for each experiment. Each protein 169 preparation was independently expressed and refolded at least two times (two biological 170 replicates), and evaluated independently on NanoDSF. Each NanoDSF scan was run in parallel 171 using at least four separate capillary tubes for each biological replicate. Each result per 172 biological replicate represents average values of these measurements. Protein folding analysis 173 results were plotted as a relationship of the normalized F350/F330 (%) ratio intensities (T_{onset}). 174 The first derivative of F350/F330 (%) intensities were plotted to obtain the thermal unfolding 175 transition midpoints (T_m) .

¹⁷⁶**Results**

177 **Clinical Genetics**

178 **Family 1 (Fig. 1):** The proband is a 10-15-year-old female born to healthy nonconsanguineous 179 parents. She referred bilaterally on newborn hearing screening. Pure tone audiometry has been 180 performed approximately every 6 months and consistently demonstrated a slowly progressive 181 mild to moderate SNHL bilaterally. Between the ages of 0-5 years and 10-15 years, there is a 182 decrease in pure tone average (PTA) of 5 dB for the right ear and 8 dB for the left ear. PTA was 183 41.25 and 38.75 in the right and left ears, respectively at age 0-5. Most recent audiometric 184 testing showed PTA of 45 and 48.75 in the right and left ears, respectively. Speech audiometry 185 at most recent evaluation (age 10-15 years) demonstrates a 90%-word recognition at a 186 comfortable listening level. Speech recognition threshold (SRT) is 45 dB bilaterally. There is a 187 history of monthly episodes of benign paroxysmal positional vertigo (BPPV) which resolved after 188 Epley maneuver. Imaging studies of the inner ear were not performed. An electrocardiogram 189 and ophthalmology exam were normal. Cytomegalovirus testing was negative. There were no 190 dysmorphic facial features, neurological or developmental abnormalities, or other pertinent 191 history. Exome sequencing revealed candidate variants only in *PKHD1L1*. Other variants were 192 excluded based on a combination of *in silico* predictors, allele frequency, and prior clinical 193 observation. The proband was compound heterozygous for missense variants, p.(Gly129Ser) 194 and p.(Gly1314Val) (Table 1) that segregated within the trio in a Mendelian recessive manner 195 (residue numbering corresponds to the NCBI human (*Hs*) sequence including the signal 196 peptide, Supplementary Table S1).

197 The p.(Gly129Ser) substitution resides in exon 4 of 78 in *PKHD1L1* and has a maximum allele 198 frequency (MAF) of 0.001471% in gnomAD (v3.1.2). This variant is predicted to be deleterious 199 to protein structure and function via *in silico* predictors (Table 1). This nonpolar glycine to polar 200 serine substitution occurs at the tip of the PKHD1L1 IPT1 domain (Fig. 2b-d). This locus is 201 predicted to be somewhat tolerant to missense substitution (Supplementary Fig. S2). On the 202 other hand, the p.(Gly1314Val), located in exon 32 of 78 in *PKHD1L1,* has a MAF of 0.07204% 203 (gnomAD, v3.1.2) and is also predicted to be deleterious to protein structure and function by *in* 204 *silico* predictors (Table 1). This glycine to valine substitution occurs within the PKHD1L1 IPT6 205 domain region (Fig. 2b-d). This locus is predicted to be intolerant to missense substitution 206 (Supplementary Fig. S2).

207 **Family 2 (Fig. 1):** The proband is a 6-10-year-old male born to healthy consanguineous 208 parents. Congenital SNHL was suspected and later clinically diagnosed. It has progressed to a 209 bilateral moderate to severe degree. Pure tone audiometry shows moderate to severe SNHL in 210 all frequencies. Speech audiometry understanding is 100% at a comfortable listening level, and 211 the otoacoustic emissions test is the reference on both ears. His SRT is 60 dB and his speech 212 discrimination score (SDS) is 100% at the intensity level of 80 dB. The proband currently uses 213 hearing aids bilaterally. There have been no vestibular or movement abnormalities. Exome 214 sequencing revealed that the proband was homozygous for the p.(Arg3381Ter) nonsense 215 variant that resided in a ~28 Mb run of homozygosity (Table 1). All other variants were excluded 216 on the basis of segregation (Supplementary Table S2). Sanger sequencing at this locus 217 confirmed the homozygous variant and revealed that the parents were both heterozygous 218 carriers of the *PKHD1L1* variant.

219 The p.(Arg3381Ter) variant is located in exon 62 of 78 and identified with a MAF of 0.01936% in 220 population databases (gnomAD, v3.1.2). This variant occurs in a region with parallel beta-helix 221 (Pbh1) repeats (Fig. 2b and Supplementary Fig. S3 for residue conservation), introducing a 222 premature stop codon that is predicted to result in the loss of approximately 20% of the 223 transcript (\sim 882 amino acids), including those encoding the transmembrane domain, and could 224 potentially cause nonsense mediated decay. However, if expressed in a truncated form, lack of 225 the transmembrane domain is likely to impair proper localization of PKHD1L1 in the cell 226 membrane or might induce unconventional secretion of PKHD1L1 protein fragments.

227 **Family 3 (Fig. 1):** The proband was a 10-15-year-old male with congenital SNHL born to 228 healthy consanguineous parents. Audiometric testing demonstrated a bilateral severe SNHL. No 229 further follow up was possible for the affected individual. Exome data analysis revealed two 230 homozygous missense variants of interest; one in *PKHD1L1* and one in *MYO7A* 231 (NM_000260.4:c.1123C>G, p.(Leu375Val)). The homozygous variant in *MYO7A* was 232 deprioritized given uncertain and neutral *in silico* predictions with respect to impact on protein 233 structure and function (Supplementary Table S2).

234 The p.(His2479Gln) substitution is located in exon 49 of 78 and is identified at a MAF of 235 0.3107% in population databases (gnomAD, v3.1.2). This positively charged histidine to neutral 236 glutamine substitution is located in a topological region with an unpredicted domain structure 237 when using the SMART prediction tool (Fig. 2b).

238 **Investigating the conservation of the mutated residue positions throughout evolution**

239 All three variants do not appear to cluster in any particular region of the PKHD1L1 isoform that 240 was used for alignment and further analysis (Supplementary Fig. S1). In comparing the longest 241 PKHD1L1 isoform sequences among 10 different species, we uncovered an overall amino acid 242 sequence identity of 79.2 % (Supplementary Fig. S3) across all 10 species. Notably, *Mm* and 243 *Hs* PKHD1L1 share 81.8% of amino acid sequence identity (when comparing for identical sites 244 excluding the signal peptides), suggesting high protein sequence conservation between the two 245 species. Although some previous studies report protein sequence alignments and predictions of 246 PKHD1L1 IPT domains (Hogan et al. 2003), an in-depth analysis was necessary to more 247 accurately predict the signal peptide cleavage sites, as well as the starting and ending residues 248 for each IPT domain. The location of the native Gly126, Gly1314, and His2479 residues, where 249 the reported missense variants were detected, are highly conserved across a diverse set of the 250 10 different PKHD1L1 orthologues analyzed (Fig. 2d-e, Fig. 3a, and Supplementary Fig. S3 and 251 Fig. S4).

252 **AlphaFold2 modeling of PKHD1L1 substitutions**

253 PKHD1L1 has 14 predicted IPT extracellular-domain repeats of similar fold but with non-254 identical protein sequence and labeled as IPT1 to IPT14 from its N-terminal to C-terminal end, 255 and other key domain features (Fig. 2b). The AlphaFold2 model of *Hs* WT IPT1-2 and its mutant 256 p.(Gly129Ser) shows no apparent differences between their predicted structures (Fig. 2f-g), 257 likely because the small side chain carrying this residue is located on a loop region exposed to 258 the solvent. More specifically, the p.(Gly129Ser) variant is located within the connecting loop 259 between the β-strand 6-7 of IPT1, close to a potential disulphide bond formed by p.Cys100 and 260 p.Cys86, also found in plexin-like domains (Fig. 2g). Changes of the polarity or the electrostatic 261 potential of this loop by p.(Gly129Ser) might cause structural changes or altered loop dynamics 262 in IPT1 (Krieger et al. 2005). We also generated AlphaFold2 models for *Hs* IPT5-6 consistent 263 with the expected IPT plexin-like folding for this structure (Fig. 2h-i). According to this structural 264 model, the *Hs* p.(Gly1314Val) mutation is also located at the connecting loop between the β-265 strand 6-7 of IPT6 (Fig. 2h-j). Furthermore, the p.(Gly1314Val) variant is located within the 266 connecting area between IPT5 and IPT6, and the AlphaFold2 model suggests a structural 267 change for this specific fragment (Fig. 2i-j).

268 In a previous study, authors used protein sequence analysis of PKHD1, PKHD1L1 and TMEM2 269 reporting that PKHD1 and PKHD1L1 share two regions of significant sequence homology with 270 TMEM2 (Hogan et al. 2003). AlphaFold2 modelling of the third variant, p.(His2479Gln) and 271 surrounding PKHD1L1 region, revealed a high structural homology with a *Hs* TMEM2 protein 272 (Fig. 3). We identified that this region features a conserved (throughout 10 different PKHD1L1 273 species, and Supplementary Fig. S4) p.His2479 residue (p.His552 in *Hs* TMEM2, Fig. 3a; PDB: 274 8C6I (Niu et al. 2023)) reported to form a nickel-finger binding site, which might mediate 275 catalytic functions in TMEM2. Disruption of this site in PKHD1L1 and TMEM2 might impair 276 cation binding (Fig. 3a-f and Supplementary Fig. S3 and S4) and suggests a potential 277 deleterious effect for this variant on protein structure and function. This locus is predicted 278 neutral in terms of tolerance to missense substitution (Supplementary Fig. S2).

279 **Functional testing of the p.(Gly129Ser) and p.(Gly1314Val) substitutions**

280 Next, we cloned, expressed, and purified WT *Mm* PKHD1L1 IPT1-3 and IPT5-6 protein 281 fragments as well as the respective IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) mutant 282 constructs using size-exclusion chromatography (SEC) (Supplementary Fig. S5). These protein 283 constructs represent key regions of the complete extracellular domain of PKHD1L1 where these 284 mutations might locally affect the structural assembly of the protein. The thermodynamic and

285 folding stabilities were measured using NanoDSF to assess the protein stabilities in solution for 286 WT PKHD1L1 protein fragments and compared to fragments carrying missense mutations (Fig. 287 4 and Supplementary Fig. S5). For WT IPT1-3, the T_{onset} (melting temperature at which 288 unfolding begins) was measured at a maximum of 58 $^{\circ}$ C, while the T_{onset} for IPT1-3 289 p.(Gly129Ser) variant was 52 °C (a 6 °C decrease, Fig. 4 and Supplementary Fig. S5). In 290 addition, there was a decrease on the T_m (melting temperature or point at which 50% of the 291 protein is unfolded) of ~ 4 °C comparing different thermal transition points between WT and the 292 IPT1-3 p.(Gly129Ser) variant (Fig. 4a). These measurements strongly suggest that the 293 p.(Gly129Ser) variant affects PKHD1L1 protein stability within this region.

294 Similarly, NanoDSF measurements for WT *Mm* PKHD1L1 IPT5-6 and *Mm* IPT5-6 295 p. (Gly1314Val) showed a T_{onset} of 35.48 °C and 28.56 °C, respectively (\sim 7 °C decrease, Fig. 4 296 and Supplementary Fig. S5). Additionally, WT *Mm* PKHD1L1 IPT5-6 showed a melting 297 temperature T_m of 45.10 °C, while the mutant IPT5-6 p. (Gly1314Val) displayed a decrease on 298 this T_m to 36.6 °C (decreasing the temperature ~ 8.6 °C) (Fig. 4b). These results confirm that 299 both IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) variants indeed significantly decrease the 300 thermal and folding stabilities of these PKHD1L1 protein constructs.

³⁰¹**Discussion**

302 A majority of congenital SNHL is attributable to a genetic etiology, and clinical genetic testing for 303 known SNHL genes is an established standard of care in the diagnostic evaluation of bilateral 304 SNHL in pediatric patients (Shearer and Smith 2015; Smith et al. 2005). There are over 120 305 known genetic causes of nonsyndromic hearing loss, and gene panel tests are recommended to 306 facilitate accurate and timely genetic diagnosis of SNHL (https://hereditaryhearingloss.org). 307 However, despite advances in genetic testing for SNHL, the diagnostic yield for SNHL ranges 308 from 22.5% to 55.7% with an average of about 40% (Downie et al. 2020; Perry et al. 2023; 309 Rouse et al. 2022; Sloan-Heggen et al. 2016). The identification of novel hearing loss genes is 310 critical to improving diagnostic rates, thus impacting care and management for individuals with 311 **SNHL.**

312 PKHD1L1 is predominantly expressed in the OHC stereocilia by P0 to P12 with a basal-to-313 apical (decreasing) expression gradient and is a major component of the stereocilia surface coat 314 (Wu et al. 2019). *Pkhd1l1*-deficient mice lack the surface coat at the stereocilia tips and exhibit 315 progressive SNHL by ABR and DPOAE measurements, starting as early as 3 weeks. The two 316 functional hypotheses of PKHD1L1 expression at the stereocilia include that it may be required

317 for the correct localization of other stereocilia proteins or during the development of attachment 318 crowns at the stereocilia to secure the tectorial membrane to the bundle. This immature 319 attachment could manifest as a persisting relaxed tectorial membrane coupling (Wu et al. 2019). 320 Still, it is unknown whether PKHD1L1 is the only component of the stereocilia coat. Recently, 321 *pkhd1l1* was shown to play a critical role in regulating hearing in zebrafish (Makrogkikas et al. 322 2023). *pkhdl1l* has a ubiquitous expression pattern and is sustained for most of embryonic 323 development (Makrogkikas et al. 2023). Through depletion of the two paralogous genes 324 (*pkhd1l1a* and *pkhd1l1b*), double mutant zebrafish exhibited significant hearing loss from the 325 larval stage (6 days post fertilization) which differs compared to progressive hearing loss in the 326 mouse (Wu et al. 2019).

327 The degree of hearing impairment in the patients we present is fairly broad: The proband in 328 family 1, with p.[(Gly129Ser)];p.[(Gly1314Val)] compound heterozygous variants, was 329 diagnosed with congenital hearing impairment that remains mild to moderate at the age of 10-15 330 years; the proband in family 2, with a homozygous p.(Arg3381Ter) variant, already showed 331 moderate to severe SNHL at the age of 6-10 years; and the proband in family 3, at the age of 332 10-15 years, showed severe hearing impairment attributed to the homozygous p. (His2479Gln) 333 variant. While we have identified individuals in three families with variants in *PKHD1L1*, this 334 study highlights the necessity for an extended case series with longitudinal audiological follow 335 up and functional studies to assess variant effects of patient-specific perturbations on 336 development, maturation, and function of the auditory system, as well as explore the potential of 337 accelerated effects of age, noise, or trauma on progression, which remain as current major 338 limitations. Interestingly, the *PKHD1L1* gene has been suggested to be associated with 339 adult-onset hearing loss (Lewis et al. 2023). Since the studied variants are also located in ass adult-onset hearing loss (Lewis et al. 2023). Since the studied variants are also located in
340 different residue positions in the PKHD1L1 protein sequence, the broad range of hearing
341 impairment from these patient 340 different residue positions in the PKHD1L1 protein sequence, the broad range of hearing 342 expression, folding, and/or the stability and function of PKHD1L1.

343 Thus, we also investigated the conservation of the mutated residue positions throughout 344 evolution. Multiple sequence alignments of the complete PKHD1L1 amino acid sequence from 345 10 different species were analysed and found to be highly conserved. This suggests that these 346 native residues might be critical to protein folding and assembly. Therefore, variants in these 347 positions might disrupt protein function and potentially cause hearing impairment *in vivo*.

348 To further predict how these PKHD1L1 mutant variants might affect the PKHD1L1 protein at the 349 structural level, we modelled the structures of the individual domains carrying reported variants

13

350 (Fig. 2f-i and Fig. 3b-e). The p.(Gly129Ser) substitution in IPT1 was not predicted to exert an 351 apparent structural difference. We speculate that instead changes of the polarity or the 352 electrostatic potential of the β-strand linker loop by p.(Gly129Ser) might alter loop dynamics in 353 IPT1. Interestingly, both glycine substitutions p.(Gly129Ser) and p.(Gly1314Val) are located 354 within the same connecting loop between β-strand 6-7 in IPT1 and IPT6, respectively. While the 355 AlphaFold2 model of the p.(Gly129Ser) mutant shows no apparent structural changes in the 356 predicted structure (Fig. 2f), the AlphaFold2 model of p.(Gly1314Val) shows a conformation 357 change, likely due to steric hindrance on the structure (Fig. 2i). Finally, we also mapped the 358 location of the p.(His2479Gln) using structural modeling by AlphaFold2 (Fig. 3, Supplementary 359 Fig. 4). Our results indicate that the His2479 position (from 10 different species) is 100% 360 conserved with a *Hs* TMEM2 protein (PDB: 8C6I), a regulator of the hyaluronan metabolism 361 (Fig. 3a and 3e-f) (Sato et al. 2023). Interestingly, experiments suggest that TMEM2 activity is 362 calcium-dependent (Yamamoto et al. 2017) and TMEM2 has been previously studied for its 363 structural similarities with the *CEMIP* deafness gene candidate (Yoshida et al. 2013).

364 Since the p.(Arg3381Ter) introduces a stop codon that would prevent the translation and 365 expression of the transmembrane domain of PKHD1L1 (Fig. 2b), the proper localization of 366 PKHD1L1 in the cell membrane is expected to be affected. Because the helical peptide of 367 PKHD1L1 transmembrane domain is predicted between p.Ile4211-4231Ala (850 amino acids 368 downstream from the Arg3381 site from the PKHD1L1 N-terminal towards the C-terminal end), 369 this large portion of the protein will not be expressed (Fig. 2b-c, Supplementary Fig. S3). This is 370 likely to impair the proper folding, trafficking, and insertion of PKHD1L1 in the stereocilia-plasma 371 membrane, or even result in secretion of PKHD1L1 extracellular fragments that could 372 progressively affect hearing function. Interestingly, secreted versions of extracellular PKHD1L1 373 have been found in supernatant solution from platelet cells (Maynard et al. 2007) and their 374 soluble concentrations could be modulated by protease inhibitors (Fong et al. 2011), suggesting 375 potential cleavage sites in *Hs* PKHD1L1. However, the role of these cleaved extracellular 376 PKHD1L1 protein fragments is still unknown.

 377 Our NanoDSF thermal folding analysis showed that both T_{onset} and T_m values decreased in the 378 presence of the p. (Gly129Ser) and p. (Gly1314Val) variants. The T_m measurements using 379 NanoDSF showed p.(Gly129Ser), located in a loop, decreases the stability of IPT1 and further 380 showed how this variant propagates its destabilizing effects to the neighboring IPT2 and IPT3 381 (Fig. 2b, Fig. 4a, and Supplementary Fig. S5). Likely, the p.(Gly1314Val) variant also alters the 382 stability of the loop and the chemical environment in the IPT5-IPT6 connection, since the

383 measured folding stability showed an 8.6 °C decrease of unfolding temperature between WT 384 IPT5-6 fragment and the p.(Gly1314Val) variant (Fig. 4). This is the first study showing strong 385 evidence to support how missense variants locally affect the structural folding and stability of 386 PKHD1L1 fragments *in vitro*. Given the high conservation rate of 81.8% in amino acid sequence 387 identity between the *Hs* and *Mm* PKHD1L1, and the 100% conservation of the mutated sites 388 across the species analyzed, we believe our findings using *Mm* PKHD1L1 protein fragments 389 can be directly applied to *Hs* PKHD1L1. Future functional studies involving full-length protein 390 purification would allow for better understanding of various effects such variants might have on 391 the stability of the entire PKHD1L1 extracellular domain, its protein expression and proper 392 localization, which might be linked to the progression and hearing loss severity. Furthermore, 393 studies focused on uncovering the influence of mutations on the structure of the complete 394 PKHD1L1 extracellular domain will help in understanding the role of PKHD1L1 in hearing 395 function and beyond, since the PKHD1L1 has been suggested as a tumor suppressor (Yang et 396 al. 2023) and a human cancer biomarker (Kafita et al. 2023; Wang et al. 2023; Zheng et al. 397 2019).

398 Additional syndromic involvement was excluded in our three patients. However, in addition to 399 hearing impairment, disruption of PKHD1L1 has also been associated with increased 400 susceptibility to pentylenetetrazol-induced seizures in mice indicating a possible role in 401 maintenance of neuronal excitability in the central nervous system (Yu et al. 2023). PKHD1L1 is 402 expressed in the hippocampus and cerebral cortex in adult WT mice. Knockdown of PHKD1L1 403 using PHKD1L1-shRNA or PHKD1L1-shRNA-AAV increased susceptibility of seizures as 404 indicated by increased epileptiform bursting activity in cultured hippocampal neurons and 405 pentylenetetrazol-induced seizures of mice following knockdown, suggesting a role for 406 PKHD1L1 in the maintenance of normal excitation-inhibition balance (Yu et al. 2023). Although 407 these findings have not been validated in *Pkhd1l1*-knockout mice, an open question remains as 408 to whether similar pleiotropic effects paralleling, for example, the various phenotypes caused by 409 pathogenic variants in *TBC1D24* may also occur as more *PKHD1L1* patients are discovered. 410 The gene-phenotype relationship of *TBC1D24* is extensive and includes both autosomal 411 dominant (DFNA65, OMIM 616044) and recessive (DFNB86, OMIM 614617) nonsyndromic 412 deafness, as well as familial infantile myoclonic epilepsy (FIME, OMIM 605021) with or without 413 deafness, early infantile epileptic encephalopathy (EIEE16, OMIM 615338), progressive 414 myoclonic epilepsy (PME, OMIM 310370), or deafness, onychodystrophy, osteodystrophy, 415 impaired intellectual development, and seizures syndrome (DOORS, OMIM 220500) (as 416 reviewed by Mucha et al. 1993; Rehman et al. 2017). Further reporting of variants in *PKHD1L1*

417 will be critical to discovering a potential parallel between *PKHD1L1* and the complex syndromes 418 using the *TBC1D24* analogy.

419 Finally, we conclude with a cautionary note for diagnostic laboratories, as this work serves as an 420 extended invitation to include *PKHD1L1* screening in their future patient diagnostic screening. 421 Determination of pathogenicity of genes causing hearing loss relies on multiple lines of 422 supporting evidence. However, in the case of large genes with large amounts of natural 423 variation, like *PKHD1L1*, the allele frequency criteria, specifically the PM2_Supporting 424 pathogenicity criteria, becomes a point of contention for classification. The PM2_Supporting 425 criterion as proposed by the ACMG/AMP hearing loss expert panel specification have calculated 426 a ≤0.00007 frequency for autosomal recessive disorders to trigger application (Oza et al. 2018). 427 With MAFs of 0.0007204 in the non-European Finnish and 0.003107 in the South Asian 428 populations (gnomAD v3.1.2), the c.3941G>T, p.(Gly1314Val) and c.7437C>A, p.(His2479Gln) 429 variants exceeded the ACMG/AMP criteria with hearing loss expert panel specification , 430 respectively, and suggests the potential for missed diagnoses if the proposed frequency is 431 applied for variant filtering (Oza et al. 2018). This merits attention because the PM2 criterion is 432 most commonly applied among the criteria for hearing loss variant classification (Kim et al. 433 2022). Given the large size of *PKHD1L1* and that more missense variants are observed than 434 expected $(Z = -0.72, o/e = 1.04 (1.02 - 1.08))$ minor allele frequency threshold usage should be 435 carefully assessed for this gene. This study is a call to clinical laboratories to include careful 436 screening of *PKHD1L1* biallelic variants in patients with a hearing loss ranging from mild-437 moderate to severe.

⁴³⁸**Conclusion**

439 Here we provide data to support *PKHD1L1* as a cause of human nonsyndromic autosomal 440 recessive congenital, mild-moderate to severe hearing loss. We demonstrated that all reported 441 missense variants are of residues highly conserved throughout evolution, suggesting that the 442 native residues are key for protein folding and function, while variants in these sites affect the 443 thermal-folding stability of PKHD1L1 fragments in solution. Inclusion as a hearing loss gene is 444 supported by multiple families segregating plausible variants, *in vitro* functional data confirming 445 the impact of variants, as well as previously published mouse and zebrafish models 446 demonstrating hearing loss. Further research will be needed to determine the effect of age, 447 noise, or trauma on progression of hearing loss.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.08.23296081;](https://doi.org/10.1101/2023.10.08.23296081) this version posted October 9, 2023. The copyright holder for this preprint

⁴⁴⁸**References**

449

450 Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, 451 Sunyaev SR (2010) A method and server for predicting damaging missense mutations. 452 Nat Methods 7: 248-9. https://doi.org/10.1038/nmeth0410-248 453 Almagro Armenteros JJ, Tsirigos KD, Sonderby CK, Petersen TN, Winther O, Brunak S, von 454 Heijne G, Nielsen H (2019) SignalP 5.0 improves signal peptide predictions using deep 455 neural networks. Nat Biotechnol 37: 420-423. https://doi.org/10.1038/s41587-019-0036-z 456 Brownell WE (1990) Outer hair cell electromotility and otoacoustic emissions. Ear Hear 11: 82- 457 92. https://doi.org/10.1097/00003446-199004000-00003 458 Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, Alföldi J, Watts NA, Vittal C, 459 Gauthier LD, Poterba T, Wilson MW, Tarasova Y, Phu W, Yohannes MT, Koenig Z, 460 Farjoun Y, Banks E, Donnelly S, Gabriel S, Gupta N, Ferriera S, Tolonen C, Novod S, 461 Bergelson L, Roazen D, Ruano-Rubio V, Covarrubias M, Llanwarne C, Petrillo N, Wade 462 G, Jeandet T, Munshi R, Tibbetts K, Consortium gP, O'Donnell-Luria A, Solomonson M, 463 Seed C, Martin AR, Talkowski ME, Rehm HL, Daly MJ, Tiao G, Neale BM, MacArthur 464 DG, Karczewski KJ (2022) A genome-wide mutational constraint map quantified from 465 variation in 76,156 human genomes. bioRxiv: 2022.03.20.485034. 466 https://doi.org/10.1101/2022.03.20.485034 467 Choudhary D, Narui Y, Neel BL, Wimalasena LN, Klanseck CF, De-la-Torre P, Chen C, Araya-468 Secchi R, Tamilselvan E, Sotomayor M (2020) Structural determinants of protocadherin-469 15 mechanics and function in hearing and balance perception. Proc Natl Acad Sci U S A 470 117: 24837-24848. https://doi.org/10.1073/pnas.1920444117 471 Consortium G (2013) The Genotype-Tissue Expression (GTEx) project. Nat Genet 45: 580-5. 472 https://doi.org/10.1038/ng.2653 473 De-la-Torre P, Choudhary D, Araya-Secchi R, Narui Y, Sotomayor M (2018) A Mechanically 474 Weak Extracellular Membrane-Adjacent Domain Induces Dimerization of Protocadherin-475 15. Biophys J 115: 2368-2385. https://doi.org/10.1016/j.bpj.2018.11.010 476 Downie L, Halliday J, Burt R, Lunke S, Lynch E, Martyn M, Poulakis Z, Gaff C, Sung V, Wake 477 M, Hunter MF, Saunders K, Rose E, Lewis S, Jarmolowicz A, Phelan D, Rehm HL, 478 Melbourne Genomics Health A, Amor DJ (2020) Exome sequencing in infants with 479 congenital hearing impairment: a population-based cohort study. Eur J Hum Genet 28: 480 587-596. https://doi.org/10.1038/s41431-019-0553-8 481 Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang HY, Speicher KD, Blair IA, 482 Speicher DW, Grosser T, Brass LF (2011) Deciphering the human platelet sheddome. 483 Blood 117: e15-26. https://doi.org/10.1182/blood-2010-05-283838 484 Hiller K, Grote A, Scheer M, Munch R, Jahn D (2004) PrediSi: prediction of signal peptides and 485 their cleavage positions. Nucleic Acids Res 32: W375-9. 486 https://doi.org/10.1093/nar/gkh378 487 Hogan MC, Griffin MD, Rossetti S, Torres VE, Ward CJ, Harris PC (2003) PKHDL1, a homolog 488 of the autosomal recessive polycystic kidney disease gene, encodes a receptor with 489 inducible T lymphocyte expression. Hum Mol Genet 12: 685-98. 490 Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, 491 Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J, 492 Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin 493 G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, Foulkes WD, 494 Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA, 495 Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W (2016) REVEL: 496 An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J 497 Hum Genet 99: 877-885. https://doi.org/10.1016/j.ajhg.2016.08.016

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.08.23296081;](https://doi.org/10.1101/2023.10.08.23296081) this version posted October 9, 2023. The copyright holder for this preprint

- 498 Jaiganesh A, De-la-Torre P, Patel AA, Termine DJ, Velez-Cortes F, Chen C, Sotomayor M 499 (2018) Zooming in on Cadherin-23: Structural Diversity and Potential Mechanisms of 500 Inherited Deafness. Structure 26: 1210-1225 e4.
- 501 https://doi.org/10.1016/j.str.2018.06.003
- 502 Kafita D, Nkhoma P, Dzobo K, Sinkala M (2023) Shedding Light on the Dark Genome: Insights 503 into the Genetic, CRISPR-based, and Pharmacological Dependencies of Human 504 Cancers and Disease Aggressiveness. bioRxiv: 2023.08.15.552589. 505 https://doi.org/10.1101/2023.08.15.552589
- 506 Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia 507 KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes 508 D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, 509 Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, 510 Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, 511 Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, 512 Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne 513 C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, 514 Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Genome Aggregation Database 515 C, Neale BM, Daly MJ, MacArthur DG (2020) The mutational constraint spectrum 516 quantified from variation in 141,456 humans. Nature 581: 434-443.
- 517 https://doi.org/10.1038/s41586-020-2308-7
- 518 Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, 519 Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A (2012) Geneious 520 Basic: an integrated and extendable desktop software platform for the organization and 521 analysis of sequence data. Bioinformatics 28: 1647-9. 522 https://doi.org/10.1093/bioinformatics/bts199
- 523 Kim SY, Kim BJ, Oh DY, Han JH, Yi N, Kim NJ, Park MK, Keum C, Seo GH, Choi BY (2022) 524 Improving genetic diagnosis by disease-specific, ACMG/AMP variant interpretation 525 guidelines for hearing loss. Sci Rep 12: 12457. https://doi.org/10.1038/s41598-022- 526 16661-x
- 527 Krieger F, Moglich A, Kiefhaber T (2005) Effect of proline and glycine residues on dynamics and 528 barriers of loop formation in polypeptide chains. J Am Chem Soc 127: 3346-52. 529 https://doi.org/10.1021/ja042798i
- 530 Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, 531 Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG (2007) Clustal W 532 and Clustal X version 2.0. Bioinformatics 23: 2947-8. 533 https://doi.org/10.1093/bioinformatics/btm404
- 534 Letunic I, Khedkar S, Bork P (2021) SMART: recent updates, new developments and status in 535 2020. Nucleic Acids Res 49: D458-D460. https://doi.org/10.1093/nar/gkaa937
- 536 Lewis MA, Schulte J, Matthews L, Vaden KI, Steves CJ, Williams FMK, Schulte BA, Dubno JR, 537 Steel KP (2023) Accurate phenotypic classification and exome sequencing allow 538 identification of novel genes and variants associated with adult-onset hearing loss. 539 medRxiv. https://doi.org/10.1101/2023.04.27.23289040
- 540 Makrogkikas S, Cheng RK, Lu H, Roy S (2023) A conserved function of Pkhd1l1, a mammalian 541 hair cell stereociliary coat protein, in regulating hearing in zebrafish. J Neurogenet: 1-8. 542 https://doi.org/10.1080/01677063.2023.2187792
- 543 Maynard DM, Heijnen HF, Horne MK, White JG, Gahl WA (2007) Proteomic analysis of platelet 544 alpha-granules using mass spectrometry. J Thromb Haemost 5: 1945-55. 545 https://doi.org/10.1111/j.1538-7836.2007.02690.x
- 546 Michalski N, Petit C (2015) Genetics of auditory mechano-electrical transduction. Pflugers Arch 547 467: 49-72. https://doi.org/10.1007/s00424-014-1552-9

642

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.08.23296081;](https://doi.org/10.1101/2023.10.08.23296081) this version posted October 9, 2023. The copyright holder for this preprint

⁶⁴³**Statements and Declarations**

⁶⁴⁴**Acknowledgments**

645 We thank the families for their participation.

⁶⁴⁶**Funding**

647 This work was supported by NIDCD K08 DC019716 to AES, the De Garay Family Fund to MAK 648 with support from the Boston Children's Rare Disease Cohort Initiative, and the German 649 Research Foundation (DFG) VO 2138/7-1 grant 469177153 to BV, and by NIH R01DC017166 650 (NIDCD) and R01DC020190 (NIDCD) to AAI. Funding for work in Pakistan was provided by the 651 University of the Punjab (SN).

652 **Author contributions**

653 SER and PD contributed equally as shared first authors and AAI, AES and BV contributed 654 equally as shared last authors. AES, PD, and AAI conceived the study. PD, TM, and AAI 655 designed methodology. PD and TM contributed software. MZ, PD, and AAI performed formal 656 analyses that were validated by MZ, MK, PD, TM, and AAI. MZ, HK, MK, SN, MAK, PD, TM, 657 AAI, and BV conducted the investigation process. HG, GS, MAK, AES, SER, and PD secured 658 patient and experimental resources. MZ, HG, GS, BV, SER, AES, PD, and AAI performed data 659 curation. BV, AES, PD, and AAI wrote the original draft. MZ, HK, MK, SN, HG, BV, SER, AES, 660 PD, and AAI contributed to reviewing and editing. BV, AES, SER, PD, and AAI prepared figures. 661 SN, AES, PD, and AAI provided supervision. BV, AES, and AAI oversaw project administration. 662 All authors reviewed and approved of the manuscript.

⁶⁶³**Data Availability**

664 All data needed to evaluate the conclusions in the paper are present in the paper and/or the 665 Supplementary Materials. Additional data related to this paper may be requested from the 666 authors.

- ⁶⁶⁷**Compliance with ethical standards**
- ⁶⁶⁸**Conflict of interest**
- 669 Go Hun Seo is an employee of 3Billion, Inc. The other authors have no conflicts to declare.
- ⁶⁷⁰**Ethics approval**

- 671 This study was approved by the institutional review boards of Boston Children's Hospital (IRB P-
- 672 00031494), University Medical Center Göttingen (No. 3/2/16), and the School of Biological
- 673 Sciences, University of Punjab, Lahore, Pakistan (IRB No. 00005281).

⁶⁷⁴**Consent to participate**

675 Written informed consent was obtained from all participants.

⁶⁷⁶**Consent to publish**

677 Consent to publish was obtained from all participants.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.08.23296081;](https://doi.org/10.1101/2023.10.08.23296081) this version posted October 9, 2023. The copyright holder for this preprint

⁶⁷⁸**Figure Legends**

679 **Fig. 1. Pedigrees & Audiograms.** Pedigree and audiometric information for three families with 680 biallelic *PKHD1L1* variations. (a) Pedigrees for families 1-3. Each proband with SNHL is 681 indicated with shading and arrow. (b) Pure tone audiometry for probands 1-3; x represents 682 results for the left ear and o represents the right. Audiometric evaluation performed at 10-15- 683 years-old, for probands 1 and 3, and 6-10-years-old, for probands 2, respectively.

- 684
- 685

686 **Fig. 2. PKHD1L1 protein domain prediction and evolutionary analysis.** (a) Schematic of a 687 hair-cell stereocilia bundle under force stimulation highlighting the stereocilia surface coat. (b) 688 Protein domain composition prediction from SMART using the *Hs* PKHD1L1 protein sequence 689 as in NCBI accession code NP 803875.2, including the signal peptide (See Supplementary 690 Table S1). Positions of each variant reported in this study is presented with a green arrowhead. 691 The red star represents a newly predicted TMEM2-like domain. Black and purple arrow-headed 692 lines represent the sequence fragments used for AlphaFold2 modelling of IPT1-2, IPT5-6, and 693 TMEM2-like domain, respectively. (c) Topological description of *Hs* PKHD1L1 protein sequence 694 as a reference. (d-e) Multiple protein sequence alignments comparing IPT1 and IPT6 domains 695 from 10 different species, respectively (see Supplementary TableS1 for details about the 696 selected species and Supplementary Fig. S3 for full PKHDL1 sequence alignment). IPT1 has a 697 sequence pairwise identity conservation of 82.3%, while IPT6 has a pairwise identity of 74.9%. 698 Missense variants are highlighted by green triangles. Blue circles represent cysteine residues 699 forming disulfide bonds showed in panels *f-i*. Each alignment was color-coded for sequence 700 similarity (35% threshold) using Jalview. White-colored residues show the lowest similarity and 701 dark blue report the highest (see Methods). Species were chosen based on sequence 702 availability and taxonomical diversity (Choudhary et al. 2020; De-la-Torre et al. 2018; Jaiganesh 703 et al. 2018). (f) Superposed AlphaFold2 models of both native *Hs* IPT1-2 (orange) and *Hs* IPT1- 704 2 p.(Gly120Ser) variant (mauve) are shown. (g) Higher magnification image of the mutated site. 705 S129 in lime and G129 in cyan. No apparent structural changes are predicted by AlphaFold2. 706 (h) Structural model of *Hs* IPT5-6 showing the native Gly1314 position. (i) Superposed *Hs* IPT5- 707 6 (orange) and *Hs* IPT5-6 p.(Gly1314Val) (mauve) structures showing a structural change 708 predicted by AlphaFold2 as a result of p.(Gly1314Val) substitution. β-strands and loops do not overlap, with a dashed black arrow reporting the loop shift. (i) Higher magnification image of the 710 mutated site showing the conformation change of β-strands and loops. V1314 (lime) cause
711 steric hindrance in the area inducing an expanded conformation to the variant structure in steric hindrance in the area inducing an expanded conformation to the variant structure in 712 mauve. See dashed arrows.

713

714

715 **Fig. 3. PKHD1L1 structural modelling of the protein fragment containing the** 716 **p.(His2479Gln) variant.** Based on AlphaFold2 predictions, this fragment of PKHD1L1 shares a

717 common fold with the TMEM2 protein within the region carrying the p.(His2479Gln) variant. (a) 718 Protein sequence alignment of a protein segment of *Hs* TMEM2 against 10 different species of 719 PKHD1L1 proteins (See Supplementary Table S1 for details of the selected species, 720 Supplementary Fig. S4 for sequence alignment of this specific fragment, and Supplementary 721 Fig. S3 for full PKHDL1 sequence alignment). Residue numbering for TMEM2 as in PDB: 8C6I 722 (Niu et al. 2023), while residue numbering for *Hs* PKHD1L1 as in NCBI accession code 723 NP_803875.2 with the signal peptide included (Supplementary Table S1, 26 residues are 724 suggested, see Methods). Green triangles point to the location of the human variant 725 p.(His2479Gln), orange circles (*left*) indicate 100% amino acid sequence identity for this 726 PKHD1L1 fragment between the *Hs*, *Pt*, and *Mm2* species (See supplementary Table S1 for 727 details about the selected species). Green circles represent depicted residues in panels *b-e*. 728 The alignment was color-coded for sequence similarity (35% threshold) using Jalview. White-729 colored residues show the lowest similarity and dark blue report the highest (see Methods). 730 Species were chosen based on sequence availability and taxonomical diversity. (b) The 731 simulated protein structure covering the protein fragment highlighted by purple arrow-headed 732 line in Fig. 2b. Front view of the structure showing IPT14 linked to the PKHD1L1 TMEM2-like 733 domain. The red star points to the linker connection. Residues at the mutation site are depicted 734 as cyan sticks. (c) Side view from *panel a* showing a clear view of the stacked β-strand motifs.
735 (d) Superposed structural protein alignment between WT Hs PKHD1L1 TMEM2-like domain 735 (d) Superposed structural protein alignment between WT *Hs* PKHD1L1 TMEM2-like domain 736 model (orange) with the X-ray crystal structure of *Hs* TMEM2 protein (PDB: 8C6I, magenta). 737 Residues at the native TMEM2-histidine finger site are depicted as green sticks. (e) Higher 738 magnification image of the potential conserved histidine-finger site between PKHD1L1 (orange) 739 and TMEM2 (magenta) protein fragments and the Ni²⁺ ion shown as lime sphere. (f) Displayed 740 residues between both proteins surrounding the Ni²⁺-ion site highlighted in *panel a* in green 741 circles.

742 743

744 **Fig. 4. Thermodynamic and folding stability evaluation of two missense variants using** 745 **NanoDSF.** (a) NanoDSF melting temperatures for WT *Mm* IPT1-3 (orange) and *Mm* IPT1-3 746 p. (Gly129Ser) variant (pink). Measurements show at least three T_m peaks (orange dotted line) 747 for the WT IPT1-3, likely because the protein fragment includes multiple IPT domains that unfold 748 sequentially. Measured T_m values are shifted to the left (pink dotted line) showing a decrease of 749 the thermal folding stability. Temperatures are labeled for each T_m transition point. (b) Results 750 for WT *Mm* IPT5-6 and *Mm* IPT5-6 p.(Gly1314Val) showing a reduced thermal stability (2 751 replicates, see Methods section). Traces correspond to the normalized first derivate of the 752 fluorescence ratio showing the inflection point of the fluorescence ratio, which corresponds to 753 the melting temperature of the sample. T_{onset} values and protein purification experiments are 754 shown in Supplementary Fig. S5.

Table

All variants are annotated according to NC_000008.11 (genomic) and NM_177531.6 (coding DNA). Residue position according to NP_803875.2 including the signal peptide (Supplementary Table S1). Abbreviations: AF, allele frequency; chr, chromosome; MAF, maximum allele frequency; MT, MutationTaster; Pop, population; PP2, PolyPhen-2; Zyg, zygosity

Family 1 \mathbf{A}

Family 2

Family 1 B

Family 2

Family 3

Family 3

